Skip to main content
      RT @Stiddyo: Using data of the E3N prospective observational study - including 98995 women - passive smoking in childhoo

      Paul Studenic Stiddyo

      4 years 5 months ago
      Using data of the E3N prospective observational study - including 98995 women - passive smoking in childhood or adulthood could be found as risk factor for #RA and potentially earlier onset #OP0012 #EULAR2021 @RheumNow https://t.co/58DJ8lZzfV
      RT @Stiddyo: Novel Results from the @rheum_covid register in #RA patients presented by @jeffsparks #OP0006
      Higher risk f

      Paul Studenic Stiddyo

      4 years 5 months ago
      Novel Results from the @rheum_covid register in #RA patients presented by @jeffsparks #OP0006 Higher risk for patients on rituximab or on JAK inhibitors for hospitalisation & ventilation or death after #COVID19 infection compared to TNFi users. #EULAR2021 @RheumNow https://t.co/40h5zVpxAO
      RT @MeralElRamahiMD: #Eular2021: Is AS & nr-AxSpA the same disease? The current consensus is that they are the two e

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      #Eular2021: Is AS & nr-AxSpA the same disease? The current consensus is that they are the two ends of the spectrum -- same disease! @RheumNow https://t.co/r0fTtp3Uip
      RT @MeralElRamahiMD: #EULAR2021 M:F ratio in nr-AxSpa is 1:1. The baseline features between r-AxSpa and nr-AxSpA is simi

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      #EULAR2021 M:F ratio in nr-AxSpa is 1:1. The baseline features between r-AxSpa and nr-AxSpA is similar with equal burden of disease. @RheumNow https://t.co/tm9Y6OB5TY
      RT @AurelieRheumo: MD, PhD ✅
      Nice milestone in a career
      Excited for the future 😎 https://t.co/cYlBEUXwQ5

      Aurelie Najm AurelieRheumo

      4 years 5 months ago
      MD, PhD ✅ Nice milestone in a career Excited for the future 😎 https://t.co/cYlBEUXwQ5
      RT @AurelieRheumo: Our meta-analysis on IA GC effects on pain and function in knee OA vs. controls at different time poi

      Aurelie Najm AurelieRheumo

      4 years 5 months ago
      Our meta-analysis on IA GC effects on pain and function in knee OA vs. controls at different time points: short term superiority of IA GC, medium term effect is no longer significant apart vs PBO and long term IA GC non superior vs controls. #EULAR2021 @RheumNow #POS1099 https://t.co/mQ0bMF03IT
      RT @AurelieRheumo: Data from E3N-EPIC cohort: passive tabagism in both childhood (HR 1.42 95CI [1.07 to 1.88]) and adult

      Aurelie Najm AurelieRheumo

      4 years 5 months ago
      Data from E3N-EPIC cohort: passive tabagism in both childhood (HR 1.42 95CI [1.07 to 1.88]) and adulthood (HR 1.27 95CI [1.02 to 1.57]) associated with higher risk of RA in non smoking women (adjusted on age passive smoking educational level BMI) #EULAR2021 @RheumNow #OP0012
      RT @AurelieRheumo: Towards personalized therapy in RA with @MeganHanlon4's work: the synovial macrophage sub-population

      Aurelie Najm AurelieRheumo

      4 years 5 months ago
      Towards personalized therapy in RA with @MeganHanlon4's work: the synovial macrophage sub-population CD206+CD163+ is significantly enriched in RA synovial tissue, correlated with disease activity and baseline levels predict response to therapy. #EULAR2021 @RheumNow #OP0028
      RT @AurelieRheumo: Insights in RA and colon:
      Naïve RA patients
      -higher degree of intestinal permeability vs age and s

      Aurelie Najm AurelieRheumo

      4 years 5 months ago
      Insights in RA and colon: Naïve RA patients -higher degree of intestinal permeability vs age and sex matched ctrls in colonic biopsies -higher serum levels of bacterial translocation markers (LBP and CD14s); reduced in resp to DMARDs. #EULAR2021 @RheumNow #OP0035 @ClaireDaien
      RT @Yuz6Yusof: Can we taper IV belimumab in #SLE? Dr Fredi reported 14/48 (29%) extended tx to at least 5-weekly after 1

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years 5 months ago
      Can we taper IV belimumab in #SLE? Dr Fredi reported 14/48 (29%) extended tx to at least 5-weekly after 12mo of tx. No worsening C3/C4 & PGA but interestingly #steroid and SLEDAI ⬇️. More works needed to identify suitable pts for taper and regime #EULAR2021 #POS0107 @RheumNow https://t.co/Gwe7mPWPdY
      RT @Yuz6Yusof: In a UK 🇬🇧 study of newly diagnosed #SLE, Dr Yee reported higher damage in the first 3yrs but then

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years 5 months ago
      In a UK 🇬🇧 study of newly diagnosed #SLE, Dr Yee reported higher damage in the first 3yrs but then stabilised. Death rate in the first 12yrs had improved to 4.8% (mostly heart disease and infection) but could still occur early (within 5yr diagnosis) #EULAR2021 #POS0111 @RheumNow
      RT @Yuz6Yusof: In patients with #SLE who attained LLDAS, a retrospective cohort study by Dr Cunha identified predictors

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years 5 months ago
      In patients with #SLE who attained LLDAS, a retrospective cohort study by Dr Cunha identified predictors of flares including anti-RNP +ve, concomitant immunosuppressant and oral prednisolone. Important to account these during follow-up #EULAR2021 #POS0105 @RheumNow
      RT @drdavidliew: Hello @IainBMcInnes1, and thanks for your president's welcome to the #EULAR2021 portal!

      Clean and stra

      David Liew drdavidliew

      4 years 5 months ago
      Hello @IainBMcInnes1, and thanks for your president's welcome to the #EULAR2021 portal! Clean and straightforward, I like it. No tour required! @eular_org @RheumNow https://t.co/RDRl4FhEZj
      RT @RheumNow: Starting Thursday we'll be covering EULAR. Tune in for coverage on KOL perspective highlights, clinical t

      Dr. John Cush RheumNow

      4 years 5 months ago
      Starting Thursday we'll be covering EULAR. Tune in for coverage on KOL perspective highlights, clinical trial highlights and much more. https://t.co/L7ryiQ5HdV
      RT @Yuz6Yusof: Do look out for Abst #OP0057 today 2/6/21 1645 CEST #EULAR2021. We propose a data-driven algorithm for #r

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years 5 months ago
      Do look out for Abst #OP0057 today 2/6/21 1645 CEST #EULAR2021. We propose a data-driven algorithm for #rituximab maintenance in #ANCA #vasculitis to avoid excessive retreatment and low IgG @RheumJArn @edvital P. Emery @LeedsMedHealth @LTHTResearch @LeedsHospitals @LeedsBRC https://t.co/XRR0NFnpMu
      ×